ABBOTT PARK, Ill., Aug. 16, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has approved two new strengths for three-month administration of ...

The FINANCIAL — Abbott Park, Illinois — Abbott announced today that the U.S. Food and Drug Administration (FDA) has approved a new 45 mg for six-month administration formulation of Lupron Depot® ...

Abbott announced that the US Food and Drug Administration (FDA) has approved two new strengths for three-month administration of Lupron Depot-PED (leuprolide acetate for depot suspension) for the ...

MUMBAI, India and WARREN, N.J., Nov. 29, 2022 /PRNewswire/ -- Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) and its wholly owned subsidiary Cipla USA Inc. (hereafter referred to as 'Cipla'), today ...

Cipla Limited and its wholly owned subsidiary Cipla USA Inc. on Tuesday has announced the launch of Leuprolide Acetate Injection Depot 22.5mg. The product was approved by the United States Food and ...

Paul Hinds, a cybersecurity expert who likes yoga and bicycling, was diagnosed with prostate cancer about five years ago. He tried multiple treatments before turning to intramuscular shots of Lupron ...

The US Food and Drug Administration (FDA) have approved Abbott’s supplemental New Drug Application (sNDA) for Lupron Depot-PED (leuprolide acetate for depot suspension). The one-month formulation is ...

The FDA is reviewing Abbott’s supplemental New Drug Application for a new six-month 45-mg formulation of Lupron Depot (leuprolide acetate for depot suspension) for the palliative treatment of advanced ...

New Delhi, Nov 29 (PTI) Drug firm Cipla on Tuesday said it has launched Leuprolide Acetate Injection Depot 22.5 mg, used in the treatment of prostate cancer. The product was earlier approved by the US ...

ABBOTT PARK, Ill., June 20, 2011 /PRNewswire/ -- Abbott announced today that the U.S. Food and Drug Administration (FDA) has approved a new 45 mg for six-month administration formulation of Lupron ...